---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-107327"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:25:17.868661+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioXcel CCO Matthew Wiley departs; severance includes 9-mo salary, consulting through 2024

## Summary
- Matthew Wiley (SVP, Chief Commercial Officer) separated on Oct 2, 2024; severance agreement signed Oct 3.
- Severance: 9 months base salary continuation, prorated 2024 bonus, 9 months COBRA reimbursement.
- Consulting agreement with Wiley's LLC at $330/hr, $7,500 retainer, runs through Dec 31, 2024.
- Standard release of claims and non-disparagement obligations included in separation agreement.

## SEC filing metadata
- accession: 0001104659-24-107327
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465924107327/0001104659-24-107327-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465924107327/tm2425903d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-107327
- JSON: https://secwatch.observer/filing/0001104659-24-107327.json
- Plain text: https://secwatch.observer/filing/0001104659-24-107327.txt

## Key facts
- Executive change
  Matthew Wiley departed as Senior Vice President and Chief Commercial Officer at BioXcel Therapeutics, Inc..
  - Action: cease employment
  - Role: Senior Vice President and Chief Commercial Officer
  source text: Matthew Wiley, Senior Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. (the “ Company ”), and the Company agreed that Mr. Wiley would cease his employment with the Company, effective October 2, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465924107327/0001104659-24-107327-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.